# A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Source: https://onco.cc/trials/nct06131450/  
OnCo record `nct06131450` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BL-M07D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies is a phase 1/2 interventional study registered as NCT06131450 by Sichuan Baili Pharmaceutical Co., Ltd., with 138 participants planned, started 2024-02-29 and due to reach its primary completion in 2026-12. Interventions recorded: BL-M07D1.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06131450
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT06131450: https://clinicaltrials.gov/study/NCT06131450

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06131450.json